On February 27, 2004, the FDA approved the oral version of Novartis Pharmaceuticals Corporation's immunosuppressant Myfortic (mycophenolic acid), allowing the company to compete directly with the dominant brand-cellcept (mycophenolate sodium). This additional formulation strengthens Novartis' portfolio in the transplant market, creating a dual-track strategy that provides physicians and patients with flexible delivery options while diversifying the company's generic revenue stream.